[The molecular bases of the pathogenesis of malaria and their potential uses in developing a combined therapy for the infection].
Molecular mimicry of a host is essential malaria parasite invasion and spreading in a host and it makes self-advantage for the parasite affecting vital organs and systems of the latter. It is tempting to assume that monoclonal antibody (MA) blocking specific (such as IMAM-I or CD36) and some unspecific (such as C3b) receptors of the blood stages of P. falciparum may prevent the malignant course of the infection. In our experience pyrazolone derivative not only suppressed schizont P. vivax infection but parasitemia too. After ceasing the drug administration, fever and parasitemia reappeared. It is of interest to study whether MA to the parasite hsp75 kD are able to suppress blood schizogony in P. falciparum infection. The prevention with MA to IFN-ů the development of experimental cerebral malaria has been reported. Principally new approach in advancing the therapy of malignant malaria might be inducing agents of TNF inhibitors production. The suppressing of the parasite activity by blocking its receptors in a host seems to be perspective in the therapy of malignant malaria.